1 of 10

KEMAL UTKU KOSMAN

INDEPENDENT INVESTMENT RESEARCH

Applied AI investment assessment

Assess Turkish-founded Applied AI companies

with venture-scale potential.

SELECTION CRITERIA

Turkish-founded, Applied / Vertical AI, venture-backed,

10+ employees and demonstrated commercial traction.

EVALUATION SCOPE

Founder-market fit, market opportunity, AI differentiation,

traction, key risks and diligence priorities.

2 of 10

APPLIED AI / INVESTMENT MEMOS

Investment framework

Four investment lenses and the evidence required to support them

KEMAL UTKU KOSMAN / APPLIED AI

02

INVESTMENT LENS

EVIDENCE TO REQUEST

DECISION TEST

01

Team

Founder track record, domain depth

and customer references.

Can this team execute in

its chosen customer workflow?

02

Market

Customer budgets, reachable buyers

and a bottom-up market model.

Is the entry market large enough

for a scalable business?

03

AI product

Data rights, performance benchmarks

and improvement with usage.

Does the AI advantage strengthen

as deployment grows?

04

Commercial pull

Paid contracts, cohort retention,

renewals and customer ROI.

Does adoption convert into

repeatable revenue?

3 of 10

APPLIED AI / INVESTMENT MEMOS

Five companies, distinct AI applications

Funding is approximate or disclosed; commercial signals are reported unless marked Est.

Figures are based on publicly available information and may vary across sources;

estimates and company-reported metrics are identified where applicable.

03

COMPANY

APPLICATION

FUNDING / STAGE

REPORTED TRACTION

​

Retail intelligence

~$13.1M

Series A

$8.3M est. 2025 revenue

70+ countries

​

Renewable asset

intelligence

~$2M

Seed

107 plants / 6,309 MW

9 countries

​

Wind blade monitoring

~$2.1M

Seed

1,000+ turbines

10 countries

​

Chronic disease

management

$3M+

Seed

300K+ patients

30+ business partners

​

Manufacturing video

analytics

~$2.2M

Seed

Reported 10–15% OEE gains

Ford, LG and Philips

Different metrics indicate different forms of traction and are not directly comparable.

4 of 10

INVESTMENT MEMO / SERIES A

Vispera

Retail intelligence

~$13.1M funding

Founded 2014 · ~79 employees · 16 reported funding rounds

INVESTMENT THESIS

Computer vision expertise and international sales support a global retail intelligence platform.

PRODUCT & TEAM

Shelf-image analysis turns retail execution into measurable, actionable store data.

​

Aytül Erçin and Ceyhun Burak Akgül combine academic and industry expertise in deep learning and computer vision.

MARKET

~$2.5B TAM / ~$738M SAM

~25.4% CAGR, 2025–2033

North America scale and

Asia-Pacific growth.

KEY RISK

Similar competitors. Public proof of superior technology remains limited.

$8.3M

estimated 2025 revenue

70+

countries (company-reported)

~65%

intl. revenue; source unconfirmed

Reported 50+ customers, including Coca-Cola, Unilever, Carlsberg, Colgate, L’Oréal, Nestlé, Reckitt and Carrefour.

Figures are based on publicly available information and may vary across sources;

estimates and company-reported metrics are identified where applicable.

04

5 of 10

INVESTMENT MEMO / SEED

Kavaken

Renewable asset intelligence

~$2M funding

Founded 2021 · ~13 employees · 4 reported funding rounds

INVESTMENT THESIS

Energy expertise and measurable operating outcomes support international asset software.

PRODUCT & TEAM

AI analyzes wind and solar operating data to detect performance losses, failure risks and corrective interventions.

​

Bora Tokyay and Murat Yılmaz bring energy engineering, operations and business development experience.

MARKET

~$9.8B TAM / ~$6.9B SAM proxy

~13% CAGR to 2032

US share ~45%. Asia-Pacific

growth ~15% CAGR.

KEY RISK

Crowded asset platforms. Repeatable ROI and international sales need proof.

6,309

MW under analysis (reported)

107

plants / 9 countries (reported)

1,511

verified cases (company-reported)

Estimated revenue $1–1.5M. TotalEnergies reportedly uses the product daily. Customers also include Borusan EnBW, Enerjisa, Eksim and Aydem.

Figures are based on publicly available information and may vary across sources;

estimates and company-reported metrics are identified where applicable.

05

6 of 10

INVESTMENT MEMO / SEED

Werover

Wind blade monitoring

~$2.1M funding

Founded 2018 · ~20 employees · 2 reported funding rounds

INVESTMENT THESIS

Proprietary acoustic data enables continuous blade monitoring for wind operators.

PRODUCT & TEAM

Acoustic sensing and machine learning detect, classify and track hidden turbine blade damage before failure.

​

Balca Yılmaz and Çağlar Erat are control engineers with renewable energy, sensing, embedded IoT and AI experience.

MARKET

~$40B wind O&M TAM

~$1.2B blade inspection SAM

Forecast growth and endpoint

require reconciliation.

KEY RISK

Established rivals. Data advantage and deployment economics need proof.

1,000+

turbines / 10 countries (reported)

4.1M

hours of blade data (reported)

~£12K

MRR; source unconfirmed

40+ blades saved (company-reported). Reported turnover ~£480K. Customers include TotalEnergies, Fred Olsen Renewables, Genpa, Eksim and Menderes Enerji.

Figures are based on publicly available information and may vary across sources;

estimates and company-reported metrics are identified where applicable.

06

7 of 10

INVESTMENT MEMO / SEED

Albert Health

Chronic disease management

$3M+ funding

Founded 2018 · 8 disclosed funding events

INVESTMENT THESIS

Enterprise distribution and clinical experience support a scalable chronic-care platform.

PRODUCT & TEAM

Patient data, personalized guidance, medication tracking and telehealth support continuous AI-enabled care.

​

Recai Serdar Gemici, Serhat Uzun and Ensar Güneşdoğdu combine commercial, enterprise and AI expertise with an in-house medical team.

MARKET

~$8.3B TAM

~13.4% CAGR to 2030

~$9.5B adjacent DTx market

Rising chronic-care demand.

KEY RISK

Clinical durability, regulation and AI differentiation remain key tests.

300K+

patients / ~5 countries (reported)

30+

business partners (reported)

64%

90-day diabetes retention (reported)

Company-reported: 5K+ monthly telehealth connections; 1.29-point mean HbA1c reduction among improved users. Partners include Roche, Pfizer, Bayer and NN Group.

Figures are based on publicly available information and may vary across sources;

estimates and company-reported metrics are identified where applicable.

07

8 of 10

INVESTMENT MEMO / SEED

Khenda

Manufacturing video analytics

~$2.2M funding

Founded 2021 · Approximately 16 employees

INVESTMENT THESIS

Camera-based analytics offer an entry into factory software without heavy sensor integrations.

PRODUCT & TEAM

Process video and existing cameras power time studies, line balancing, downtime analysis and continuous improvement.

​

Çağkan Ekici and Aykan Ekici bring machine vision and industrial automation experience, including factory vision software R&D.

MARKET

~$9.7B TAM (2026)

~$5.7B SAM proxy*

~46.5% CAGR to ~$47.9B (2030)

*Software and services

KEY RISK

MES and analytics competition. ROI must repeat across factory deployments.

10–15%

early OEE gains (company-reported)

$200K

up to, one CNC station (reported)

2

products: CI platform + Vision MES

Customers include Ford Automotive, LG Electronics, Philips, Hengst and ISAIC. ISO 27001 certified, SOC 2 Type II audit completed. North America expansion focus.

Figures are based on publicly available information and may vary across sources;

estimates and company-reported metrics are identified where applicable.

08

9 of 10

APPLIED AI / INVESTMENT MEMOS

Evidence status by company

Source types across five investment questions. Colors do not indicate investment quality.

Figures are based on publicly available information and may vary across sources;

estimates and company-reported metrics are identified where applicable.

09

E

Third-party estimate

C

Company claim

K

Customer case

U

Source unconfirmed

—

No data in review

COMPANY

REVENUE

CUSTOMER ROI

/ IMPACT

RETENTION

AI DIFFERENTIATION

INTERNATIONAL

SALES

Vispera

E

$8.3M estimate

K

Retail cases

—

No cohort data

C

CV capability

U

~65% intl. share

Kavaken

U

$1–1.5M estimate

K

Operator cases

—

No cohort data

C

Predictive models

C

9-country footprint

Werover

U

~£12K MRR

C

40+ blades saved

—

No cohort data

C

Acoustic models

C

10-country footprint

Albert Health

—

Not disclosed

C

Clinical outcomes*

C

64% at 90 days

C

Condition-specific AI

U

~5-country footprint

Khenda

—

Not disclosed

K

Factory case

—

No cohort data

C

Video analytics

—

No quantified sales

Cases are company-published customer examples. *Clinical outcomes are not financial ROI.

Footprints do not establish international revenue. “No data” refers only to the reviewed material.

10 of 10

INVESTMENT COMMITTEE / DILIGENCE AGENDA

Evidence that changes conviction

Prospective diligence outcomes for each investment thesis

COMPANY

EVIDENCE THAT SUPPORTS THE THESIS

FINDINGS THAT WEAKEN THE THESIS

Vispera

High renewals and recurring revenue.

Clear wins against competing products.

Service-heavy revenue or high churn.

Little performance advantage.

Kavaken

Verified savings and paid-MW expansion.

Renewals with attractive cost to serve.

Savings fail to repeat across plants.

Service effort absorbs gross profit.

Werover

Accurate detection with few false alerts.

Healthy margins after hardware costs.

False alerts undermine operator trust.

Hardware and support erode margins.

Albert Health

Durable outcomes in controlled cohorts.

Retention supports viable care economics.

Selection bias explains outcome gains.

Weak retention or regulatory barriers.

Khenda

ROI repeats across independent sites.

Pilots convert into recurring contracts.

Gains rely on bespoke projects.

Low conversion or costly deployment.

Across all five: valuation, ownership, runway and round terms remain open.

KEMAL UTKU KOSMAN / APPLIED AI

10